Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. (symbol: PYXS) is a clinical stage biotechnology company focused on the development of next-generation therapeutics designed to combat difficult-to-treat cancers. The company's mission is to enhance the body's immune response to cancer by targeting specific tumor micro-environments, employing cutting-edge antibody-drug conjugates (ADCs) and immuno-oncology (IO) strategies. Pyxis Oncology aims to improve the quality of life for cancer patients through innovative treatments that directly kill tumor cells and address the pathological factors that enable cancer's proliferation and immune evasion.
Pyxis Oncology is currently developing multiple therapeutic candidates, including PYX-201 and PYX-106, which are in Phase 1 clinical studies targeting a variety of solid tumors. These candidates are designed to be effective both as monotherapies and in combination with existing treatments, providing versatile approaches to cancer therapy. PYX-201 is being evaluated for its safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in patients with advanced solid tumors. Similarly, PYX-106 is being assessed in a first-in-human, open-label, multicenter Phase 1 clinical study.
In addition to its robust pipeline, Pyxis Oncology is backed by substantial financial support from institutional investors such as Deep Track Capital, Ridgeback Capital Investments L.P., Blue Owl Healthcare Opportunities, Laurion Capital Management, and StemPoint Capital L.P. Recently, the company secured additional financing to further its research and development efforts, with Leerink Partners and LifeSci Capital serving as placement agents for the private placement.
Pyxis Oncology is committed to translating its preclinical findings into effective clinical treatments. The company has also actively participated in key industry conferences, such as the Society for Immunotherapy of Cancer (SITC) annual meeting, where its research on PYX-201, PYX-106, and other candidates was presented through posters and oral presentations.
Looking forward, Pyxis Oncology has outlined several anticipated milestones, including upcoming financial results for Q4 and the full year 2023, and further updates on their clinical programs. Investors and stakeholders can stay informed through regular updates and detailed news releases.
For more information, visit the Pyxis Oncology website or contact Pamela Connealy, CFO and COO, at ir@pyxisoncology.com.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company developing next-generation cancer therapeutics, has announced its participation in two upcoming investor conferences. CEO Lara S. Sullivan will engage in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6 at 12:20 PM ET and the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 2:00 PM ET, both in New York.
Management will also participate in one-on-one meetings during these events. Investors can access live webcasts and replays of the presentations through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website at ir.pyxisoncology.com.
Pyxis Oncology (PYXS) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Preliminary data from PYX-201 Phase 1 trial expected in fall 2024
- Preliminary data from PYX-106 Phase 1 trial expected by year-end 2024
- Cash runway extended into 2H 2026
- $157.2 million in cash and investments as of June 30, 2024
- 72 subjects dosed in PYX-201 trial, 33 in PYX-106 trial
- Q2 2024 R&D expenses: $13.9 million (up from $11.4 million in Q2 2023)
- Q2 2024 net loss: $17.3 million or ($0.29) per share
The company remains focused on developing next-generation therapeutics for difficult-to-treat cancers, with ongoing clinical trials for PYX-201 and PYX-106.
Pyxis Oncology, a clinical stage company developing next-gen cancer therapies, announced its participation in the BTIG Virtual Biotechnology Conference. The event is scheduled for August 5-6, 2024. Lara S. Sullivan, M.D., President and CEO of Pyxis, along with other management members, will engage in one-on-one meetings during the conference.
This participation highlights Pyxis Oncology's commitment to advancing its pipeline of therapeutics targeting difficult-to-treat cancers. The company's presence at this virtual event provides an opportunity for investors and industry professionals to gain insights into Pyxis's ongoing developments and strategic direction in the oncology field.
Pyxis Oncology, a clinical stage company, announced the grant of restricted stock units and stock options to five new employees under its 2022 Inducement Plan. The total grants include 89,530 shares of common stock and options to purchase 111,913 shares at an exercise price of $3.31 per share. These awards, aligned with Nasdaq Listing Rule 5635(c)(4), serve as an inducement for employment and will vest over four years. The initial 25% of the grants will vest on the first anniversary, with the remaining shares vesting monthly over the subsequent three years.
Pyxis Oncology (Nasdaq: PYXS) has appointed Michael A. Metzger to its Board of Directors, effective June 10, 2024. Metzger brings over 25 years of biopharmaceutical experience and is currently the CEO of Syndax Pharmaceuticals. Pyxis CEO Lara S. Sullivan emphasized Metzger's expertise and leadership in innovation as vital for the company's growth, particularly in advancing their antibody-drug conjugates (ADCs) aimed at treating challenging cancers. Metzger expressed enthusiasm for contributing to Pyxis's mission of improving cancer treatment outcomes.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on next-generation cancer therapeutics, announced that its President and CEO, Lara S. Sullivan, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:00 AM Eastern Time in New York City. The management team will also hold one-on-one meetings with investors. The event will be webcast live, with a replay available on the company's Investor Relations website.
Pyxis Oncology (Nasdaq: PYXS) announced its Q1 2024 financial results and corporate updates. PYX-201's Phase 1 trial has dosed 42 patients and aims to dose 16 more, with readout expected in fall 2024. PYX-106's Phase 1 trial, targeting NSCLC and other cancers, has dosed 24 patients, with data expected in 2H 2024. The company presented new preclinical data and expanded its leadership team with Stephen Worsley as Chief Business Officer. Q1 2024 financial highlights include revenues of $16.1M, R&D expenses of $13M, and a net loss of $3.3M. Cash runway is expected to last into 2H 2026.
Pyxis Oncology, Inc. (Nasdaq: PYXS) will be presenting at the RBC Capital Markets Global Healthcare Conference where the President and CEO will participate in a fireside chat and host investor meetings. The event will take place on May 14, 2024, at 3:05 PM ET.
FAQ
What is the current stock price of Pyxis Oncology (PYXS)?
What is the market cap of Pyxis Oncology (PYXS)?
What is Pyxis Oncology, Inc.?
What are the company's core products?
What is the focus of Pyxis Oncology's research?
Who are some of Pyxis Oncology's investors?
What recent achievements has Pyxis Oncology announced?
What is the purpose of PYX-201?
How does PYX-106 differ from PYX-201?
What future milestones has Pyxis Oncology outlined?
How can I contact Pyxis Oncology?
Where can I find more information about Pyxis Oncology’s presentations?
